FUNDAMENTALS
EdgeFII/DII
LUPINLupin
₹2,014.00+0.76%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
LUPINNSE · EquityPharmaceuticals

Lupin

ISIN
INE326A01037
Instrument key
NSE_EQ|INE326A01037
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹2,014.00+15.20 · +0.76%
Day rangecircuit ₹1,812.60 – ₹2,215.40
1,985.10
2,014.00

as of 21/11/2026, 1:01:03 pm

Open
₹1,992.00
Day high
₹2,014.00
Day low
₹1,985.10
Prev. close
₹1,998.80
Volume
6.31 L
VWAP
₹1,995.55

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

5 years · weekly candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M6M
1Y
5Y
MAX
Change · 5Y
+124.10%
898.70 → 2,014.00
Period high
₹2,529.50
13/7/2026
Period low
₹583.00
23/5/2022
From high
-20.38%
+245.45% from low
Avg volume
54.20 L
142.01 Cr total
Volatility · ann.
24.2%
262 candles · 143 up / 119 down
16 Nov 2026O 1,982.30H 2,014.00L 1,946.20C 2,014.00Vol 29.77 L
SMA 20SMA 50Averages need 50 candles before they begin
Candle data262 rows of open, high, low, close and volumeShowHide
16 Nov 20261,982.302,014.001,946.202,014.00+1.60%67.8029.77 L
9 Nov 20261,997.402,036.501,980.301,980.30-0.86%56.2026.79 L
2 Nov 20262,019.802,062.101,944.101,997.00-1.13%118.0048.32 L
26 Oct 20261,928.002,021.801,912.402,011.00+4.30%109.4030.16 L
19 Oct 20261,955.801,971.601,892.901,928.90-1.38%78.7026.66 L
12 Oct 20261,955.901,990.901,925.701,961.60+0.29%65.2033.56 L
5 Oct 20262,015.402,031.401,936.901,956.50-2.92%94.5033.99 L
28 Sept 20262,087.902,098.602,004.202,031.20-2.72%94.4033.83 L
21 Sept 20262,084.002,135.002,077.502,092.00+0.38%57.5026.40 L
14 Sept 20262,095.002,114.702,033.502,083.00-0.57%81.2031.10 L

Historical price and volume data · Showing 1–10 of 262

1 / 27

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

17.6
Company
17.6
Sector
-45.02

Worse than sector by 139%

P/B

Price ÷ book value per share

3.82
Company
3.82
Sector
4.21

Better than sector by 9%

ROA

Net income ÷ total assets

13.08%
Company
13.08%
Sector
1.19%

Better than sector by 999%

ROE

Net income ÷ shareholders' equity

21.65%
Company
21.65%
Sector
-0.4%

Better than sector by 5512%

ROCE

EBIT ÷ capital employed

24.54%
Company
24.54%
Sector
15.44%

Better than sector by 59%

Quick Ratio

Liquid assets ÷ current liabilities

1.42
Company
1.42
Sector
4.8

Worse than sector by 70%

EV/EBITDA

Enterprise value ÷ EBITDA

10.24
Company
10.24
Sector
22.86

Better than sector by 55%

04/Business

About the company

Sector: Pharmaceuticals

Lupin Limited is a global pharmaceutical company, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates in India and the United States across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti-Inflammatory Drug therapy segments and operates in the Anti-TB and Cephalosporins segments. Its generic formulations include Filgrastim, Peg filgrastim, Etanercept and Albuterol. Its diabetes brands include Gibtulio, Ajaduo, Gibtulio Met, ONDERO and ONDERO MET. Its other brands include AntaGolin, RyChol and others. Its Huminsulin range of products includes Insulin Human.

Sector market cap (INR)
₹91,916 Cr

reported in crore

Sector market cap (USD)
$10.21B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Consolidated income statement

Annual figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Mar 2026
₹28,382 Cr
+23.92% vs Mar 2025
Net profit · Mar 2026
₹5,355 Cr
+61.98% vs Mar 2025
Operating margin
24.2%
was 17.5%
Revenue CAGR · 4p
19.3%
profit 128.7% · op 112.5%
Filed order
Revenue28,38222,90420,13116,715
Revenue growthreported23.9%13.8%20.4%—
Operating profit6,8734,0152,422716
Operating profit growthreported71.2%65.8%238.1%—
Operating marginderived24.2%17.5%12.0%4.3%
Net profit5,3553,3061,936448
Net profit growthreported62.0%70.8%332.4%—
Net marginderived18.9%14.4%9.6%2.7%
EPS — basic₹/share, annual116.7571.9542.059.46

Figures in ₹ crore. Margin rows are computed from the reported values.

06/Balance sheet

Consolidated balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹38,365 Cr
+31.36% YoY
Total liabilities
₹15,851 Cr
Net worth
₹22,513 Cr
Liabilities ÷ assets
41.3%
lower means a lighter balance sheet
Filed order
Total assets38,36529,20523,99722,956
Total liabilities15,85111,9119,62410,413
Net worthderived22,51317,29414,37312,543
Liabilities ÷ assetsderived41.3%40.8%40.1%45.4%
Asset growthderived31.4%21.7%4.5%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets14,33712,40610,55010,505
Current Assets24,02716,79913,44812,451
Total Assets38,36529,20523,99722,956
Current Liabilities12,6518,9618,5029,265
Net Current Asset11,3767,8374,9463,186
Non-Current Liabilities3,2002,9491,1221,148
Equity Capital22,51317,29414,37312,543
Total Equity & Liabilities38,36529,20523,99722,956

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Consolidated cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹7,335 Cr
+144.49% YoY
Investing
-₹3,865 Cr
Financing
-₹846 Cr
Free cash flow
₹3,470 Cr
operating + investing
Filed order
Operating activities7,3353,0003,6481,897
Operating changereported144.5%-17.8%92.3%—
Investing activities-3,865-4,172-1,712-1,287
Investing changereported7.4%-143.7%-33.1%—
Financing activities-8461,732-2,184-337
Financing changereported-148.8%179.3%-547.6%—
Net cash flowderived2,624560-248273
Free cash flowoperating + investing3,470-1,1721,936610

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax6,8734,0152,422716
Income before WC changes7,9685,3173,8891,814
Change in Assets-1,814-1,239-702-112
Change in Liabilities2,447-172788438
Change in WC634-1,41186327
Cash flow from Operations7,3353,0003,6481,897
Cash flow from Investing-3,865-4,172-1,712-1,287
Cash flow from Financing-8461,732-2,184-337
Total Cash Flow2,624560-248273
Cash (Start of the year)1,5449841,232991
Cash (End of the year)4,1681,5449841,265

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
46.85%
0.00 pts QoQ
FII
23.28%
+0.86 pts QoQ
DII (other)
9.20%
-0.61 pts QoQ
Mutual funds
14.58%
-0.26 pts QoQ
Retail & others
6.09%
+0.01 pts QoQ
Filed order
Promoters46.9%46.9%46.9%46.9%
FII23.3%22.4%21.7%21.5%
DII (other)9.2%9.8%8.4%7.6%
Mutual funds14.6%14.8%16.9%18.0%
Retail & others6.1%6.1%6.1%6.0%
Promoters — QoQ changepts, derived0.0%-0.0%-0.0%—
FII — QoQ changepts, derived0.9%0.7%0.2%—
DII (other) — QoQ changepts, derived-0.6%1.4%0.8%—
Mutual funds — QoQ changepts, derived-0.3%-2.1%-1.1%—
Retail & others — QoQ changepts, derived0.0%-0.0%0.1%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

DividendFinal₹18.00900.0%17 Jul 202617 Jul 202607 May 2026

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

SUNPHARMASUN Pharmaceutical IND LPharmaceuticals₹1,884.90-0.79%19.16 L₹4,52,299 Cr$50.26B
DIVISLABDivi S Laboratories LtdPharmaceuticals₹11,180.50+0.02%4.05 L₹2,97,325 Cr$33.04B
TORNTPHARMTorrent Pharmaceuticals LPharmaceuticals₹4,689.50+1.70%2.00 L₹1,78,727 Cr$19.86B
LAURUSLABSLaurus Labs LimitedPharmaceuticals₹2,294.60-0.49%8.79 L₹1,24,002 Cr$13.78B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
DRREDDYDR. Reddy S LaboratoriesPharmaceuticals₹1,390.20-0.76%8.31 L₹1,16,145 Cr$12.90B
CIPLACipla LtdPharmaceuticals₹1,415.00-0.25%14.84 L₹1,14,312 Cr$12.70B
MANKINDMankind Pharma LimitedPharmaceuticals₹2,665.00+1.37%4.56 L₹1,09,870 Cr$12.21B
AUROPHARMAAurobindo Pharma LtdPharmaceuticals₹1,799.00-0.37%8.11 L₹1,03,298 Cr$11.48B
GLENMARKGlenmark PharmaceuticalsPharmaceuticals₹2,648.00+1.51%5.40 L₹74,733 Cr$8.30B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

No news in the last seven days

Company news is available for a rolling one-week window.

Full annual line itemsRevenue, other income, expenses, tax, EPS
ShowHide
Filed order
Revenue27,95822,70820,01116,642
Other Income1,081202131151
Total Revenue29,03922,91020,14216,793
Total Expenses21,60818,89517,71916,076
Profit Before Tax6,8734,0152,422716
Tax1,517709487269
Profit After Tax5,3553,3061,936448
EPS - Basic116.7571.9542.059.46
EPS - Diluted116.4471.6941.879.41

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.